MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 10-31-2024
Syros Pharmaceuticals Net Income 2011-2026 | SYRS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Syros Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -165 M | -94.7 M | -86.6 M | -84 M | -75.4 M | -62.3 M | -54 M | -47.7 M | -29.8 M | -13.4 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.4 M | -165 M | -71.3 M |
Quarterly Net Income Syros Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.4 M | -23.3 M | -3.71 M | - | -40.1 M | -36.3 M | -23.8 M | - | -30.3 M | -34.5 M | -25.1 M | - | -26 M | -22.5 M | -14.2 M | -30.1 M | -84 M | -84 M | -84 M | -19.7 M | -75.4 M | -75.4 M | -75.4 M | -18 M | -62.3 M | -62.3 M | -62.3 M | -15.3 M | -54 M | -54 M | -54 M | -11 M | -47.7 M | -47.7 M | -47.7 M | -10.7 M | -29.8 M | -29.8 M | -4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.71 M | -84 M | -39.6 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.35 | -2.91 % | $ 359 M |  Britain |
 |
Coherus BioSciences
CHRS
|
168 M | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
214 M | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-78.5 M | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Cardiff Oncology
CRDF
|
-45.9 M | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-147 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Dyadic International
DYAI
|
-7.36 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Entera Bio Ltd.
ENTX
|
-9.98 M | $ 1.17 | -2.1 % | $ 64 M |  Israel |
 |
Equillium
EQ
|
-22.4 M | $ 2.0 | -0.5 % | $ 115 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Evogene Ltd.
EVGN
|
-30.4 M | $ 0.8 | 2.49 % | $ 27.9 M | Israel |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
-136 M | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Forte Biosciences
FBRX
|
-69.4 M | $ 26.15 | -1.1 % | $ 339 M | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fennec Pharmaceuticals
FENC
|
-9.74 M | $ 6.2 | -3.43 % | $ 177 M | USA |
|
Foghorn Therapeutics
FHTX
|
-74.3 M | $ 4.75 | -2.59 % | $ 299 M | USA |
 |
Amicus Therapeutics
FOLD
|
-27.1 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
10.3 B | $ 88.37 | -3.19 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 3.52 | -0.56 % | $ 237 B | Britain |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-74.9 M | $ 7.45 | -4.85 % | $ 472 K | USA |
 |
Galectin Therapeutics
GALT
|
-30.8 M | $ 2.38 | -7.03 % | $ 152 M | USA |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Gilead Sciences
GILD
|
8.51 B | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-7.52 M | $ 0.54 | 4.26 % | $ 503 K | Israel |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Genmab A/S
GMAB
|
4.76 B | $ 27.13 | -2.25 % | $ 17 B |  Danmark |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |